Compare Pfizer Inc (PFE) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B). The key difference: Pfizer Inc is far larger — about 36.5× State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF's market cap, and Pfizer Inc pays a 6.18% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| PFE | SJNK | |
|---|---|---|
Market Cap | $158.56B | $4.35B |
Volume | 44,138,282 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $29.02 | $25.57 |
52-Week Low | $23.67 | $24.13 |
Typical Hold Time | 158 Days | 41 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.18 with a slight 24-hour decline of 0.08%. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF has maintained consistent dividend payments recently, with three distributions of $0.14-$0.15 scheduled for late 2026. Institutional activity shows mixed sentiment with Cetera Investment Advisers and Balefire LLC reducing positions in recent quarters.
The ETF faces headwinds from the current bearish technical setup while offering yield advantages over Treasury securities. Key risks include interest rate sensitivity and high-yield bond market volatility. Investors should weigh the attractive dividend yield against the technical weakness and institutional selling pressure when considering position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
